Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ANIX - Anixa Biosciences Inc

IEX Last Trade
2.55
0   0%

Share volume: 0
Last Updated: Thu 26 Dec 2024 05:25:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$2.55
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 16%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-22.29%
3 Months
-18.87%
6 Months
8.86%
1 Year
-33.16%
2 Year
-34.52%
Key data
Stock price
$2.55
P/E Ratio 
0.00
DAY RANGE
$2.54 - $3.50
EPS 
$0.00
52 WEEK RANGE
$2.25 - $5.13
52 WEEK CHANGE
-$33.68
MARKET CAP 
106.902 M
YIELD 
N/A
SHARES OUTSTANDING 
32.006 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09/06/2024
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$82,614
AVERAGE 30 VOLUME 
$81,125
Company detail
CEO: Amit D. Kumar
Region: US
Website: anixa.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Anixa Biosciences, Inc. develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company is also developing immuno-therapy drugs against cancer.

Recent news